Novo Nordisk alleges fraud after US$1.3 billion deal to buy hypertension drug from Singapore-based KBP Biosciences
Novo Nordisk is seeking up to US$830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...
Seeking Alpha17d
Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)
Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity ...